D
Dyfrig A. Hughes
Researcher at Bangor University
Publications - 275
Citations - 10165
Dyfrig A. Hughes is an academic researcher from Bangor University. The author has contributed to research in topics: Cost effectiveness & Randomized controlled trial. The author has an hindex of 47, co-authored 255 publications receiving 8328 citations. Previous affiliations of Dyfrig A. Hughes include RMIT University & University of Liverpool.
Papers
More filters
Journal ArticleDOI
A new taxonomy for describing and defining adherence to medications
Bernard Vrijens,Sabina De Geest,Sabina De Geest,Dyfrig A. Hughes,Kardas Przemyslaw,Jenny Demonceau,Todd M. Ruppar,Todd M. Ruppar,Fabienne Dobbels,E.A. Fargher,Val Morrison,Paweł Lewek,Michał Matyjaszczyk,Comfort Mshelia,Wendy Clyne,Jeffrey K Aronson,John Urquhart +16 more
TL;DR: In response to the proliferation of ambiguous or unquantifiable terms in the literature on medication adherence, this research has resulted in a new conceptual foundation for a transparent taxonomy, focused on promoting consistency and quantification in terminology and methods.
Journal ArticleDOI
Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group.
Trevor Richter,Sandra Nestler-Parr,Robert Babela,Zeba M. Khan,Theresa Tesoro,Elizabeth Molsen,Dyfrig A. Hughes +6 more
TL;DR: Despite variation in the terminology and prevalence thresholds used to define rare diseases among different jurisdictions and organizations, the terms "rare disease" and "orphan drug" are used most widely and the average prevalence threshold is between 40 and 50 cases/100,000 people.
Journal ArticleDOI
Is exercise effective in promoting mental well-being in older age? A systematic review
TL;DR: Mental well-being in later life is modifiable through exercise and physical activity, and economic evidence indicated incremental cost-effectiveness ratios of £7300 and £12,100 per quality adjusted life year gained for community-based walking and exercise programmes, respectively.
Journal ArticleDOI
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
Athimalaipet V Ramanan,Andrew D. Dick,Ashley P Jones,Andrew McKay,Paula R Williamson,Sandrine Compeyrot-Lacassagne,Ben Hardwick,Helen Hickey,Dyfrig A. Hughes,Patricia Woo,Diana Benton,Clive Edelsten,Michael W. Beresford +12 more
TL;DR: Adalimumab therapy controlled inflammation and was associated with a lower rate of treatment failure than placebo among children and adolescents with active JIA‐associated uveitis who were taking a stable dose of methotrexate.
Journal ArticleDOI
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.
Dyfrig A. Hughes,F. Javier Vilar,Charlotte C Ward,Ana Alfirevic,B. Kevin Park,Munir Pirmohamed +5 more
TL;DR: Abacavir hypersensitivity is associated with HLA B*5701, and pre-prescription pharmacogenetic testing for this appears to be a cost-effective use of healthcare resources.